The Polepharma Microbiomics Days
Smaltis is delighted to have participated in and sponsored, for the fourth consecutive year, the Polepharma Microbiomics Days, held in Rouen on November 22 and 23, 2023.
This annual event on translational research and the applications of microbiota science is always a rich and exciting opportunity, fostering exchanges and debates with the aim of advancing research, developments, and regulatory issues in the field of the microbiome.
The goal of these days, JPM23, was to bring together more than 180 decision-makers and stakeholders from academic and clinical research, startups, biotechs, and pharma industries to discuss the therapeutic potential of the microbiome.
The two days were filled with conferences, roundtable discussions, workshops, and dedicated networking sessions. The 2023 edition brought together more than a hundred people for 18 conferences, 1 roundtable, 7 pitch sessions, and a total of 7 hours of networking time.
Chaired by Professor Pierre Déchelotte (Head of the Nutrition Department, Rouen Normandie University Hospital, INSERM Unit – University of Rouen U1073), the programming committee, including our CEO Cédric Muller, defined the themes for this fourth edition:
– Tissue Microbiome and Cancer
– Microbiome and Liver Diseases
– Microbiome and Antibiotic Resistance
– Methodological Challenges and Opportunities (Digital Twins)
– Development and Optimization of Bioproduction
– Research Funding to Industrialization
The contacts made and relationships established have allowed us to identify key partnerships to advance microbiome study models and deepen discussions around solutions and services to accelerate the development of new products derived from the microbiome.
Find here video of the event.
We hope that these days will continue to bring together more stakeholders in this field, fostering regular exchanges, synergies of expertise, and common decisions to further explore the vast potential of microbiomes for various health applications within a rigorous scientific framework.